Paeds Vivas · clinical-pharmacology-and-therapeutics
Cardiovascular medicines in children — branching viva
Branching viva on cardiovascular medicines in children: the prostaglandin E1 resuscitative plan for a duct-dependent neonate, the adenosine response to a compromised tachycardic child, the milrinone evidence for low cardiac output syndrome, and the carvedilol and single-ventricle enalapril trial evidence that shapes paediatric heart failure prescribing.
On this page
Study tools
Target exams
Opening — the cyanotic neonate
Examiner: A two-day-old neonate is cyanotic, tachypnoeic and acidotic, with a suspected duct-dependent lesion. Walk me through your immediate pharmacological management. [10]
Candidate (model): I would not wait for echocardiography. I would start an intravenous prostaglandin E1 (alprostadil) infusion immediately at 0.01 to 0.05 microgram per kilogram per minute and titrate upward toward a maximum around 0.1 microgram per kilogram per minute, watching for a rising saturation toward a target of 75 to 85 per cent, a warming perfusion, and a falling lactate. I would secure the airway and have an intubation plan ready, because apnoea is a common adverse effect. I would recognise fever and hypotension as further drug effects, not sepsis, though I would still take cultures and consider antibiotics. Prostaglandin E1 is a bridge to definitive anatomy repair, so I would organise retrieval to a cardiac centre at once. [10]
References6ShowHide
- [2]Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA, 2007.PMID 17848651
- [3]Hsu DT, Zak V, Mahony L, et al. Enalapril in infants with single ventricle: results of a multicenter randomized trial. Circulation, 2010.PMID 20625111
- [4]Hsu DT, Pearson GD Heart failure in children: part II: diagnosis, treatment, and future directions. Circ Heart Fail, 2009.PMID 19808380
- [6]Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation, 2003.PMID 12600913
- [7]Batra AS, Silka MJ, Borquez A, et al. Pharmacological Management of Cardiac Arrhythmias in the Fetal and Neonatal Periods: A Scientific Statement From the American Heart Association. Circulation, 2024.PMID 38314551
- [10]Taksande A, Jameel PZ Critical Congenital Heart Disease in Neonates: A Review Article. Curr Pediatr Rev, 2021.PMID 33605861